Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655033 | 0.85 | MEN1 (0.63) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL14655065 | 0.82 | HSD11B1 (0.63) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL7838313 | 0.82 | GPR119 (0.62) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL441012 | 0.80 | KDM4E (0.62) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL17594737 | 0.80 | STS (0.55) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL16225262 | 0.79 | HSD11B1 (0.60) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL5245718 | 0.79 | NPC1 (0.54) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL29200527 | 0.78 | KMT2A (0.52) | KMT2AMEN1STSPTPN2PTPN1 | |
| SCHEMBL14256143 | 0.77 | JAK2 (0.46) | KMT2AMEN1STSGPR119 | |
| SCHEMBL13859102 | 0.76 | STS (0.50) | KMT2AMEN1STSPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501513-B1 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | VERSI GROUP LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476280-B2 | Modulate contraction, relaxation of muscles | VERSI GROUP, LLC (US) | 2013-07-02 | — | — | US | disclosed |
| EP-1501513-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | Ardent Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | VERSI GROUP, LLC | 2004-01-01 | — | — | US | disclosed |
| WO-2003094853-A2 | COMPOSITIONS AND METHODS FOR COMBATING LOWER URINARY TRACT DYSFUNCTIONS WITH DELTA OPIOID RECEPTOR AGONISTS | ARDENT PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002503-A1 | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists | OPRD1, OPRK1, OPRM1 | KMT2A 4381/4885MEN1 4885/4885STS 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.